3E Bioventures Capital — 2015 Investments

1 investments dated 2015 · listed companies and verified rows first · show all

C4 Therapeuticsc4therapeutics.comin 𝕏NASDAQ: CCCCDec 2015

C4 Therapeutics develops small molecule medicines called degraders that use targeted protein degradation (TPD) to eliminate disease-causing proteins via the body's ubiquitin proteasome system.

BiotechCambridge, US

Marc Cohen(Executive Officer, Director)Jason Fisherman(Executive Officer, Director)Miles Stuchin(Director)William M. Scalzulli(Director)Kenneth Anderson(Director)Malcolm S. Salter(Director)

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.